Amir Moheet

Endocrinologist, clinical researcher, tweets are my own

[UMN Medicine @umn_dom]

📣 Calling all undergraduate students interested in pursuing a career in Medicine. Apply for the HOT Division Summer Internship Research Program❗️

View program and application details ➡️:https://t.co/zPWPsMmXHa…

Application cycle open until 2/29 🎉

[Amir Moheet @AmirMoheet]

Looking forward to the upcoming annual meeting of the Midwest chapter of @TheAACE. Great job by the program committee and the MWES leadership. Chance to network and catchup with local endocrine colleagues. Registration is free. #endotwitter
https://t.co/rdRFPj8CpX

[Stephen Stone, MD @DiabetesNinja]

Mic drop 🎤 moment of #ADA2023 @AniaJastreboff and David D’Alessio presenting too good to be true data on Retatrutide for obesity.

[Amir Moheet @AmirMoheet]

Retatrutide in #NAFLD #ADA2023 phase 2 sub study data presented by Dr. Arun Sanyal. With RETA 8 and 12 mg, hepatic steatosis resolved in >85% of participants at 48 weeks.

[Amir Moheet @AmirMoheet]

Phase 2 trial results of Retatrutide triple receptor agonist in #obesity at #ADA2023 strong weight reduction and improvement in metabolic outcomes . Full paper available now @NEJM

[Amir Moheet @AmirMoheet]

Presenting our groups work at #ADA2023 on the potential role of opioid antagonist therapy on impaired hypoglycemia counterregualtory response after exercise in diabetes #diabetes #hypoglycemia

[Amir Moheet @AmirMoheet]

Great session #ADA2023 on use of CGM in pre-diabetes, obesity and early type 2 diabetes. More research is needed to examine how CGM can be utilized for risk assessment and prevention #diabetes

[Amir Moheet @AmirMoheet]

Looking forward to the symposium on #cysticfibrosis endocrinology in era of modulator therapy ⁦@ECFSConference⁩ #CFRD #trikafta https://t.co/oVGOkLgTNI

[Amir Moheet @AmirMoheet]

Interesting case of IgG4-related hypophysitis with literature review by mentees Dr. Hiba Hashmi and Dr. Dinkar Rupakul #MedTwitter
https://t.co/PewOjj2YhX https://t.co/skiWZHiAO1

[Cystic Fibrosis Foundation @CF_Foundation]

Curious about the latest research in cystic fibrosis genetics, genetic-based therapies, lung transplant, nutrition, CFRD, or infections? You don’t want to miss ResearchCon, a free, virtual event April 26-27! All are welcome and encouraged to attend. https://t.co/XJbRVvQKeq

[Amir Moheet @AmirMoheet]

Our new paper examining impact of #Trikafta on body composition in people with #cysticfibrosis. Trikafta resulted in increased Wt and fat mass, muscle mass did not change. insulin secretion and insulin resistance increased. @LarsonOde @christinechan66 https://t.co/6frHHhqW2l

[Amir Moheet @AmirMoheet]

#CysticFibrosis #CFRD @LarsonOde

[ISPAD @ispad_org]

📆🖋️ Mark your calendar!

The next ISPAD's Educational Webinar will be on April 5 at 8 pm CET!

"Revised and updated ISPAD guidelines 2022: Cystic fibrosis-related diabetes and Type 2 Diabetes in youth"

REGISTER HERE 👉 https://t.co/UdWiImPRAW

#ISPAD

[Vin Tangpricha, MD, PhD @vtangpricha]

Nice review in press at #EndocrinePractice by @AmirMoheet on Hypoglycemia: Clinical Presentation and Diagnostic Approach to #Hypoglycemia in Adults Without #Diabetes Mellitus #EndoTwitter https://t.co/893TjHK7FW

[Amir Moheet @AmirMoheet]

@terrilaguna congratulations

[Amir Moheet @AmirMoheet]

Deeply honored to be invited as the keynote speaker at the UW CF/Diabetes Symposium. Thank you @RebeccaLHull for the invitation. Excellent presentation by Dr. Lina Merjaneh @CF_Foundation ENVISION Endocrinology scholar. Great discussion on management of #CFRD in the era of HEMT

[Amir Moheet @AmirMoheet]

@UMN_DOMResearch congratulations @dgmashek @MintTasma, Anne Bantle, Lisa Chow et al.

[Amir Moheet @AmirMoheet]

Median HbA1c decreased but there were no changes in glucose measures on OGTT. Insulin secretion increased, however, measures of insulin resistance also increased, and β-cell function adjusted for insulin sensitivity did not change. No change in CGM based outcomes.

[Amir Moheet @AmirMoheet]

Our new paper examining measures of insulin secretion and resistance in people with #cysticfibrosis before and after initiation of the highly effective CFTR modulator elexacaftor/tezacaftor/ivacaftor.#CFRD #trikafta @christinechan66 @LarsonOde
https://t.co/SqATrn08pu

[Amir Moheet @AmirMoheet]

@LizzieAbyMD @ThomasLeventhal @UMN_GI @VAMinneapolis @BilalMohammadMD @umn_dom @EugeniaShmidtMD @JoshuaASloanDO1 @gurutrikumd @BJHansonMD @mspibddoc @Mary_J_Thomson @llnordlars @NickMcDonaldMD @mabdallahmd Congratulations @ThomasLeventhal

[Vin Tangpricha, MD, PhD @vtangpricha]

Dr Moheet @AmirMoheet describes top two two non pulmonary diseases are cystic fibrosis related diabetes and bone disease. Important for endocrinologists. #NAFC2022